"if pivotal mono is to start, GvHD, TNBC to ramp up with multiple trial sites, about 4m or so cash per month will still be needed."

I'm just curious - how did you arrive at 4m or so cash per month, and at what point in 2020? I'm only asking because even though the number of patients for the P3 mono trial will increase relatively fast, I'm expecting it to take a while for all three trials (Mono, GvHD, TNBC) to be fully enrolled due to the ramp up time. To me, that means there's going to be a significant drop in expenses for a while (Q1, 2020) following the BLA submittal, as Trding suggested. I see this as a significant plus on the sp because it will provide financial relief until additional licensing/financial deals close while the other trials ramp up.